Puma Biotechnology Company Profile (NYSE:PBYI)

About Puma Biotechnology (NYSE:PBYI)

Puma Biotechnology logoPuma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NYSE:PBYI
  • CUSIP: N/A
  • Web: www.pumabiotechnology.com/
Capitalization:
  • Market Cap: $3.97 billion
  • Outstanding Shares: 37,205,000
Average Prices:
  • 50 Day Moving Avg: $89.99
  • 200 Day Moving Avg: $67.46
  • 52 Week Range: $28.35 - $109.85
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -21.49
  • P/E Growth: 0.02
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $3.24 per share
  • Price / Book: 32.96
Profitability:
  • EBIDTA: ($289,010,000.00)
  • Return on Equity: -217.17%
  • Return on Assets: -160.32%
Debt:
  • Current Ratio: 3.12%
  • Quick Ratio: 3.12%
Misc:
  • Average Volume: 927,909 shs.
  • Beta: 0.35
  • Short Ratio: 6.75
 

Frequently Asked Questions for Puma Biotechnology (NYSE:PBYI)

What is Puma Biotechnology's stock symbol?

Puma Biotechnology trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBYI."

How were Puma Biotechnology's earnings last quarter?

Puma Biotechnology Inc (NYSE:PBYI) issued its quarterly earnings data on Wednesday, August, 9th. The company reported ($2.10) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.32) by $0.78. View Puma Biotechnology's Earnings History.

When will Puma Biotechnology make its next earnings announcement?

Puma Biotechnology is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Puma Biotechnology.

Where is Puma Biotechnology's stock going? Where will Puma Biotechnology's stock price be in 2017?

9 brokers have issued 1-year target prices for Puma Biotechnology's shares. Their predictions range from $88.00 to $136.00. On average, they anticipate Puma Biotechnology's share price to reach $113.11 in the next twelve months. View Analyst Ratings for Puma Biotechnology.

Who are some of Puma Biotechnology's key competitors?

Who are Puma Biotechnology's key executives?

Puma Biotechnology's management team includes the folowing people:

  • Alan H. Auerbach, Chairman of the Board, President, Chief Executive Officer
  • Charles R. Eyler, Senior Vice President - Finance and Administration, Treasurer
  • Richard P. Bryce, Chief Scientific Officer, Chief Medical Officer
  • Steven Lo, Chief Commercial Officer
  • Jay M. Moyes, Independent Director
  • Adrian M. Senderowicz M.D., Independent Director
  • Troy E. Wilson Ph.D. J.D., Independent Director
  • Frank E. Zavrl, Independent Director

Who owns Puma Biotechnology stock?

Puma Biotechnology's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (6.82%), Vanguard Group Inc. (6.69%), Janus Henderson Group PLC (5.03%), BlackRock Inc. (4.95%), State Street Corp (3.29%) and PointState Capital LP (1.64%). Company insiders that own Puma Biotechnology stock include Adage Capital Partners Gp, LL, Alan H Auerbach, Richard Paul Bryce and Robert Charnas. View Institutional Ownership Trends for Puma Biotechnology.

Who sold Puma Biotechnology stock? Who is selling Puma Biotechnology stock?

Puma Biotechnology's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Schroder Investment Management Group, Farallon Capital Management LLC, State Street Corp, Ameriprise Financial Inc., PointState Capital LP, Federated Investors Inc. PA and Candriam Luxembourg S.C.A.. Company insiders that have sold Puma Biotechnology stock in the last year include Adage Capital Partners Gp, LL, Alan H Auerbach, Richard Paul Bryce and Robert Charnas. View Insider Buying and Selling for Puma Biotechnology.

Who bought Puma Biotechnology stock? Who is buying Puma Biotechnology stock?

Puma Biotechnology's stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Franklin Resources Inc., Bain Capital Public Equity Management LLC, HealthCor Management L.P., BlackRock Inc., Quantitative Investment Management LLC, Laurion Capital Management LP and TD Asset Management Inc.. View Insider Buying and Selling for Puma Biotechnology.

How do I buy Puma Biotechnology stock?

Shares of Puma Biotechnology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Puma Biotechnology's stock price today?

One share of Puma Biotechnology stock can currently be purchased for approximately $106.80.


MarketBeat Community Rating for Puma Biotechnology (NYSE PBYI)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  279 (Vote Outperform)
Underperform Votes:  200 (Vote Underperform)
Total Votes:  479
MarketBeat's community ratings are surveys of what our community members think about Puma Biotechnology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Puma Biotechnology (NYSE:PBYI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 8 Buy Ratings
Consensus Rating:Buy (Score: 2.89)
Consensus Price Target: $113.11 (5.91% upside)

Analysts' Ratings History for Puma Biotechnology (NYSE:PBYI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/11/2017Credit Suisse GroupBoost Price TargetOutperform -> Outperform$118.00 -> $136.00MediumView Rating Details
9/6/2017Barclays PLCInitiated CoverageOverweight$103.00HighView Rating Details
8/10/2017Stifel NicolausReiterated RatingBuy$118.00 -> $110.00HighView Rating Details
8/9/2017J P Morgan Chase & CoSet Price TargetBuy$105.00HighView Rating Details
8/2/2017Leerink SwannReiterated RatingOutperform$125.00LowView Rating Details
7/22/2017Cowen and CompanyReiterated RatingOutperform$91.00 -> $120.00MediumView Rating Details
7/21/2017Bank of America CorporationReiterated RatingBuy$100.00 -> $117.00LowView Rating Details
7/17/2017Royal Bank Of CanadaSet Price TargetHold$88.00MediumView Rating Details
7/18/2017Citigroup Inc.Reiterated RatingBuy$114.00MediumView Rating Details
1/5/2016Berenberg BankUpgradeHold -> BuyN/AView Rating Details
(Data available from 9/21/2015 forward)

Earnings

Earnings History for Puma Biotechnology (NYSE:PBYI)
Earnings by Quarter for Puma Biotechnology (NYSE:PBYI)
Earnings History by Quarter for Puma Biotechnology (NYSE PBYI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($2.50)N/AView Earnings Details
8/9/2017Q2 2017($1.32)($2.10)ViewN/AView Earnings Details
5/10/2017Q1 2017($2.06)($1.97)ViewN/AView Earnings Details
3/1/2017Q4($1.92)($2.04)ViewN/AView Earnings Details
5/10/2016Q1($1.99)($1.28)ViewN/AView Earnings Details
2/29/2016Q4($1.95)($1.23)ViewN/AView Earnings Details
11/9/2015Q3($1.84)($1.87)ViewN/AView Earnings Details
8/10/2015Q2($1.55)($1.13)ViewN/AView Earnings Details
5/11/2015Q1($1.25)($1.02)ViewN/AView Earnings Details
3/2/2015($1.15)($1.59)ViewN/AView Earnings Details
11/10/2014($1.27)($1.19)ViewN/AView Earnings Details
8/11/2014Q214($0.66)($1.05)ViewN/AView Earnings Details
5/12/2014($0.48)($0.67)ViewN/AView Earnings Details
3/3/2014Q413($0.49)($0.46)ViewN/AView Earnings Details
4/1/2013Q413($0.70)($0.25)ViewN/AView Earnings Details
11/14/2012Q312($1.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Puma Biotechnology (NYSE:PBYI)
Current Year EPS Consensus Estimate: $-8.67 EPS
Next Year EPS Consensus Estimate: $-4.97 EPS

Dividends

Dividend History for Puma Biotechnology (NYSE:PBYI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Puma Biotechnology (NYSE:PBYI)
Insider Ownership Percentage: 22.70%
Institutional Ownership Percentage: 80.98%
Insider Trades by Quarter for Puma Biotechnology (NYSE:PBYI)
Institutional Ownership by Quarter for Puma Biotechnology (NYSE:PBYI)
Insider Trades by Quarter for Puma Biotechnology (NYSE:PBYI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/7/2017Richard Paul BryceSVPSell15,000$100.09$1,501,350.00View SEC Filing  
7/20/2017Alan H AuerbachInsiderSell13,175$94.73$1,248,067.75View SEC Filing  
7/20/2017Richard Paul BryceSVPSell1,998$94.48$188,771.04View SEC Filing  
7/3/2017Richard Paul BryceSVPSell5,000$87.10$435,500.00View SEC Filing  
6/12/2017Adage Capital Partners Gp, L.LMajor ShareholderSell247,260$80.32$19,859,923.20View SEC Filing  
6/5/2017Adage Capital Partners Gp, L.LMajor ShareholderSell507,128$87.84$44,546,123.52View SEC Filing  
5/26/2017Adage Capital Partners Gp, L.LMajor ShareholderSell1,235,700$75.38$93,147,066.00View SEC Filing  
2/1/2017Robert CharnasInsiderSell3,008$31.83$95,744.64View SEC Filing  
1/20/2017Alan H AuerbachInsiderSell10,202$33.24$339,114.48View SEC Filing  
1/20/2017Richard Paul BryceSVPSell2,293$33.24$76,219.32View SEC Filing  
7/6/2015Richard Paul BryceSVPSell3,000$110.03$330,090.00View SEC Filing  
11/8/2013Adage Capital Partners Gp Llcmajor shareholderBuy22,549$38.92$877,607.08View SEC Filing  
11/5/2013Adage Capital Partners Gp Llcmajor shareholderBuy280,700$39.60$11,115,720.00View SEC Filing  
10/9/2013Adage Capital Partners Gp Llcmajor shareholderBuy140,900$40.44$5,697,996.00View SEC Filing  
12/18/2012Adage Capital Partners Gp LlcMajor ShareholderBuy29,560$19.00$561,640.00View SEC Filing  
12/12/2012Adage Capital Partners Gp LlcMajor ShareholderBuy30,400$19.00$577,600.00View SEC Filing  
12/11/2012Adage Capital Partners Gp LlcMajor ShareholderBuy140,040$18.98$2,657,959.20View SEC Filing  
10/24/2012Thomas MalleyDirectorBuy10,000$16.00$160,000.00View SEC Filing  
10/18/2012Adage Capital Partners Gp LlcMajor ShareholderBuy610,000$16.00$9,760,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Puma Biotechnology (NYSE:PBYI)
Latest Headlines for Puma Biotechnology (NYSE:PBYI)
Source:
DateHeadline
finance.yahoo.com logoPuma Biotechnology to Present at Cantor Fitzgerald Healthcare Conference
finance.yahoo.com - September 19 at 6:24 AM
prnewswire.com logoStocks Under Scanner in the Biotech Space -- Puma Biotech, Regeneron Pharma, Sarepta Therapeutics, and Seattle ... - PR Newswire (press release)
www.prnewswire.com - September 14 at 9:01 AM
finance.yahoo.com logoBefore You Buy Puma Biotechnology Inc’s (PBYI), You Should Consider This
finance.yahoo.com - September 14 at 9:01 AM
americanbankingnews.com logoCredit Suisse Group Increases Puma Biotechnology Inc (PBYI) Price Target to $136.00
www.americanbankingnews.com - September 11 at 10:44 AM
americanbankingnews.com logoPuma Biotechnology Inc (PBYI) Now Covered by Analysts at Barclays PLC
www.americanbankingnews.com - September 10 at 5:16 PM
businesswire.com logoPuma Biotechnology Presents 5-Year Analysis of Phase III ExteNET Trial in Extended Adjuvant HER2-Positive Breast ... - Business Wire (press release)
www.businesswire.com - September 10 at 6:20 AM
americanbankingnews.com logoPuma Biotechnology Inc (PBYI) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - September 9 at 11:46 AM
streetinsider.com logoPuma Biotech (PBYI) Presents 5-Year Analysis of Phase III ExteNET Trial in Extended Adjuvant HER2-Positive Breast Cancer at ESMO
www.streetinsider.com - September 9 at 7:13 AM
finance.yahoo.com logoPuma Biotechnology Presents 5-Year Analysis of Phase III ExteNET Trial in Extended Adjuvant HER2-Positive Breast Cancer at ESMO 2017 Congress
finance.yahoo.com - September 9 at 7:13 AM
americanbankingnews.com logoPuma Biotechnology Inc (PBYI) SVP Richard Paul Bryce Sells 15,000 Shares
www.americanbankingnews.com - September 8 at 7:32 PM
americanbankingnews.com logoPuma Biotechnology Inc (PBYI) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - September 8 at 10:10 AM
americanbankingnews.com logo Brokerages Anticipate Puma Biotechnology Inc (PBYI) to Announce -$2.36 EPS
www.americanbankingnews.com - September 8 at 2:28 AM
finance.yahoo.com logoPuma Biotechnology Announces Publication of Abstracts for ESMO 2017
finance.yahoo.com - August 31 at 8:35 AM
businesswire.com logoPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Business Wire (press release)
www.businesswire.com - August 27 at 5:30 AM
finance.yahoo.com logoPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - August 26 at 8:10 AM
americanbankingnews.com logo$7.16 Million in Sales Expected for Puma Biotechnology Inc (PBYI) This Quarter
www.americanbankingnews.com - August 22 at 9:44 AM
americanbankingnews.com logoZacks: Analysts Anticipate Puma Biotechnology Inc (PBYI) to Post -$2.36 EPS
www.americanbankingnews.com - August 20 at 10:42 AM
americanbankingnews.com logoPuma Biotechnology Inc (PBYI) Downgraded by BidaskClub
www.americanbankingnews.com - August 16 at 9:34 PM
seekingalpha.com logoPuma Biotech Stock Offers Opportunity To Cash In On Its Maiden Product Launch
seekingalpha.com - August 16 at 6:39 AM
americanbankingnews.com logoPuma Biotechnology Inc (PBYI) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - August 15 at 1:00 PM
nasdaq.com logoPuma Biotechnology Becomes Oversold (PBYI)
www.nasdaq.com - August 12 at 6:43 AM
nasdaq.com logoPuma (PBYI) Q2 Loss Narrower than Expected, Nerlynx in Focus - Nasdaq
www.nasdaq.com - August 11 at 7:24 AM
finance.yahoo.com logoPuma (PBYI) Q2 Loss Narrower than Expected, Nerlynx in Focus
finance.yahoo.com - August 11 at 7:24 AM
americanbankingnews.com logoPuma Biotechnology Inc (PBYI) Posts Earnings Results, Misses Estimates By $0.78 EPS
www.americanbankingnews.com - August 11 at 12:40 AM
americanbankingnews.com logoPuma Biotechnology Inc (PBYI) Stock Rating Reaffirmed by Stifel Nicolaus
www.americanbankingnews.com - August 10 at 7:46 PM
finance.yahoo.com logoPuma Biotechnology Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 10 at 6:43 AM
finance.yahoo.com logoPuma Biotech reports 2Q loss
finance.yahoo.com - August 10 at 6:43 AM
prnewswire.com logoPUMA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC ... - PR Newswire (press release)
www.prnewswire.com - August 6 at 1:14 AM
finance.yahoo.com logoShould You Buy Puma Biotechnology (PBYI) Ahead of Earnings?
finance.yahoo.com - August 5 at 6:00 AM
finance.yahoo.com logoPUMA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Puma Biotechnology, Inc. - PBYI
finance.yahoo.com - August 5 at 6:00 AM
streetinsider.com logoPuma Biotech (PBYI) Receives Day-180 List of Outstanding Issues from CHMP Related to Neratinib MAA
www.streetinsider.com - August 4 at 6:49 AM
nasdaq.com logoWhat's in Store for Puma (PBYI) this Earnings Season?
www.nasdaq.com - August 4 at 6:49 AM
nasdaq.com logoFDA Panel Snubs JNJ, CHMP Seeks More Data From PBYI, TBPH On Watch, AGRX Slumps - Nasdaq
www.nasdaq.com - August 3 at 6:48 AM
businesswire.com logoPuma Biotechnology Receives Day-180 List of Outstanding Issues from Committee for Medicinal Products for Human ... - Business Wire (press release)
www.businesswire.com - August 3 at 6:47 AM
finance.yahoo.com logoWhat's in Store for Puma (PBYI) this Earnings Season?
finance.yahoo.com - August 3 at 6:47 AM
finance.yahoo.com logoPuma Biotechnology Receives Day-180 List of Outstanding Issues from Committee for Medicinal Products for Human Use (CHMP)
finance.yahoo.com - August 3 at 6:47 AM
americanbankingnews.com logoPuma Biotechnology Inc (PBYI) Earns Outperform Rating from Leerink Swann
www.americanbankingnews.com - August 2 at 9:50 AM
americanbankingnews.com logoZacks: Analysts Anticipate Puma Biotechnology Inc (PBYI) Will Post Earnings of -$2.10 Per Share
www.americanbankingnews.com - August 2 at 7:58 AM
finance.yahoo.com logoPuma Announces Availability of NERLYNX™ (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in the United States
finance.yahoo.com - August 1 at 1:15 AM
businesswire.com logoPUMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the ... - Business Wire (press release)
www.businesswire.com - July 30 at 7:56 PM
nasdaq.com logoCommit To Purchase Puma Biotechnology At $65, Earn 13.4% Using Options
www.nasdaq.com - July 29 at 6:12 AM
finance.yahoo.com logo3 Been-There-Done-That Biotech CEOs Who Are Doing it Again
finance.yahoo.com - July 29 at 6:12 AM
finance.yahoo.com logoPUMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Puma Biotechnology, Inc. – PBYI
finance.yahoo.com - July 29 at 6:12 AM
americanbankingnews.com logoPuma Biotechnology Inc (NYSE:PBYI) SVP Richard Paul Bryce Sells 1,998 Shares
www.americanbankingnews.com - July 24 at 7:29 PM
americanbankingnews.com logoPuma Biotechnology Inc (NYSE:PBYI) Insider Sells $1,248,067.75 in Stock
www.americanbankingnews.com - July 24 at 7:28 PM
americanbankingnews.com logoCowen and Company Reaffirms "Outperform" Rating for Puma Biotechnology Inc (NYSE:PBYI)
www.americanbankingnews.com - July 22 at 10:56 AM
americanbankingnews.com logoPuma Biotechnology Inc (NYSE:PBYI) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - July 21 at 12:54 PM
americanbankingnews.com logoBank of America Corporation Reaffirms "Buy" Rating for Puma Biotechnology Inc (NYSE:PBYI)
www.americanbankingnews.com - July 21 at 9:30 AM
americanbankingnews.com logoPuma Biotechnology Target of Unusually High Options Trading (PBYI)
www.americanbankingnews.com - July 21 at 7:18 AM
benzinga.com logoPuma Biotechnology Boosted After FDA Approves Breast Cancer Therapy - Benzinga
www.benzinga.com - July 19 at 3:43 PM

Social

Chart

Puma Biotechnology (PBYI) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by MarketBeat.com Staff